CASE REPORTS
CLINICAL TRIAL
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Terlipressin for catecholamine-resistant septic shock in children.

OBJECTIVE: To report the effects of terlipressin treatment in four paediatric patients with catecholamine-resistant hypotensive septic shock.

DESIGN AND SETTING: Case report in the pediatric intensive care unit of a university hospital.

PATIENTS: Four children with severe septic shock and hypotension resistant to high doses of norepinephrine and other cathecolamines.

INTERVENTIONS: Terlipressin was added to the standard treatment, by intravenous bolus at a dose of 0.02 mg/kg every 4 h during a maximum time of 3 days.

MEASUREMENT AND RESULTS: In all cases, terlipressin induced a rapid and sustained improvement in mean arterial pressure, which allowed the lessening or even withdrawal of norepinephrine infusion. No related adverse effects were detected.

CONCLUSION: Terlipressin might be considered, at least as a rescue therapy, for hypotension resistant to catecholamines in children with septic shock. Further studies are needed to confirm the beneficial effects found in our patients. The optimal administration schedule remains to be elucidated.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app